Health Trials

Discontinuation of Antithrombotic Treatment Following Patent Foramen Ovale Closure in Young Patients With Cryptogenic Stroke

ConditionsPatent Foramen OvaleIschemic StrokeBleeding Ulcer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorJosep Rodes-Cabau

About this trial

To determine the safety of antithrombotic treatment discontinuation 12 months following successful transcatheter PFO closure.

Eligibility criteria

Qualifiers

Successful transcatheter PFO closure with any approved device

Patients ≤60 years diagnosed with a cryptogenic stroke/TIA who have undergone successful transcatheter PFO closure

Disqualifiers

RoPE score <6

Residual shunt ≥moderate following PFO closure

Atrial fibrillation following PFO closure

Presence of ≥2 cardiovascular risk factors (smoking, hypertension, dyslipidemia)

Trial design

Treatments tested in this trial

  • Antiplatelet treatment discontinuation

Treatment groups

100 Participants
are divided into 1 treatment group

Sponsors and collaborators

Josep Rodes-Cabau

Lead sponsor

Institut universitaire de cardiologie et de pneumologie de Québec, University Laval

Sponsor institution

Source ClinicalTrials.gov